Abstract

Chemotherapy regimens have been widely used in the treatment of a variety of human malignancies including hepatocellular carcinoma (HCC). A major cause of failure in chemotherapy is drug resistance of cancer cells. Resistance to doxorubicin (DOX) is a common and representative obstacle to treat cancer effectively. Individual microRNA (miRNA) has been introduced in the evolution of DOX resistance in HCC in recent studies. However, a global and systematic assessment of the miRNA expression profiles contributing to DOX resistance is still lacking. In the present study, we applied high-throughput Illumina sequencing to comprehensively characterize miRNA expression profiles in both human HCC cell line (HepG2) and its DOX-resistant counterpart (HepG2/DOX). A total of 269 known miRNAs were significantly differentially expressed, of which 23 were up-regulated and 246 were down-regulated in HepG2/DOX cells, indicating that part of them might be involved in the development of DOX resistance. In addition, we have identified 9 and 13 novel miRNAs up- and down-expressed significantly in HepG2/DOX cells, respectively. miRNA profiling was then validated by quantitative real-time PCR for selected miRNAs, including 22 known miRNAs and 6 novel miRNAs. Furthermore, we predicted the putative target genes for the deregulated miRNAs in the samples. Function annotation implied that these selected miRNAs affected many target genes mainly involved in MAPK signaling pathway. This study provides us a general description of miRNA expression profiling, which is helpful to find potential miRNAs for adjunct treatment to overcome DOX resistance in future HCC chemotherapy.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common virus-associated cancers resulting in high mortality worldwide [1]. For some patients who are not appropriate for surgical treatments, one has to only rely on chemotherapy. However, the development of drug resistance towards chemotherapeutic agents often prevents the successful long-term use of chemotherapy for HCC. Drug resistance, whether intrinsic or acquired over time, becomes the main cause of clinical treatment failure. Therefore, reversing drug resistance has become an emergent issue in tumor treatment. Drug resistance is a multifactorial phenomenon involving many mechanisms, including gene mutation, DNA methylation, altered metabolism and disposition of drugs, altered quantity or activity of target proteins and so on [2–6]. Unfortunately, the key underlying mechanisms of the acquisition of resistance to chemotherapeutic agents still remain largely unexplored [2,7].

MiRNAs are endogenously expressed small non-coding RNAs of 18–25 nucleotides in length that can post-transcriptionally regulate gene expression across various biological processes [8–12]. Growing evidences have revealed that miRNAs are important regulators in many signaling pathways involved in tumor pathogenesis [8,9,13]. MiRNA signature has been identified as pathological markers for HCC diagnostic discriminator and predictive prognosis of patients [2,14,15]. They might serve as tumor suppressors or oncogenes and constitute ideal targets in exploring anticancer therapeutics [6,16,17]. Besides, overwhelming efforts have been exerted in analyzing the role of miRNAs in the development of drug resistance in tumor cells. Blower et al. and Liu et al. carried out systematical studies respectively to explore the correlation between miRNA expression levels and drug activity across the NCI-60 cell lines (HepG2 not included) [18,19]. Tomimaru and colleagues reported that miRNA-21 is a significant modulator of the anti-tumor effect of interferon (IFN)-α/5-fluorouracil (5-FU) using quantitative real-time RT-PCR.
Materials and Methods

Cell culture
The human hepatocarcinoma cell line HepG2 was obtained from Cell Bank of Chinese Academy of Sciences (Shanghai, China) and maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO₂. The DOX-resistant variant of HepG2 cells (HepG2/DOX) was established by continuous culture in medium containing stepwise increasing concentration of DOX at a range of 0.5 to 25 μM over a period of 10 months. After 10 months of culturing in the presence of DOX, the 50% inhibitory concentration (IC₅₀) values were 23 and 0.6 μM DOX for the HepG2/DOX and parental HepG2 cells, respectively.

RNA extraction
Total RNA was extracted from HepG2 and HepG2/DOX using TRIzol (Invitrogen, US) in accordance with the manufacturer’s protocol. RNA samples then passed the RNA quality control for deep sequencing.

Small RNA library construction and sequencing
Small RNA library construction and sequencing were conducted as previously described [25,26]. Briefly, small RNAs with 18–30 nt in length were first isolated from total RNA through size fractionation using 15% tris-borate-EDTA (TBE) urea polyacrylamide gel. The separated small RNAs were then ligated to 5’ adaptor (5’-GGUGAGUUCAUGACGAGGACGU) and 3’ adaptor (5’-UGCGAUGGCGUCUUCUGUUGUdT). The ligated RNAs were size fractionated on a 15% TBE urea polyacrylamide gel again and then the excised RNAs with 5’ and 3’ adaptors were reversely transcribed to cDNA with the RT primer (CAAGCAGAGACGCGCATACGA). The cDNA was taken as a template for PCR amplification using primer set (5’-CAAGCAGAGACGCGCATACGA; 3’-AATGATACGGCGACGTCTGCTCGTGG). After purification and quantification, the resulting PCR products were sequenced on the Illumina Cluster Station and Genome Analyzer II (Illumina Inc., USA) following the manufacturer’s protocol.

Detection of differentially expressed miRNAs and prediction of target genes
Detection of differentially expressed miRNAs between HepG2 and HepG2/DOX cells was similar as described previously [25]. If the adjusted P-values were <0.05 based on the Benjamini and Hochberg multiple testing correction [30,31] and there was at least a 2-fold change ((HepG2/DOX)/HepG2) in the normalized expression level, one could consider the miRNAs as significantly differentially expressed. The target genes for each differentially expressed miRNA were mainly predicted by Mirmap (http://sourceforge.net/projects/mirmap) [25]. Given that the prediction softwares often suffer from high false positive rates, we used other three tools to assist the prediction, including miRanda (http://
Validation of miRNA expression by quantitative RT-PCR

Assays to quantify the known and novel miRNAs were done by using miScript PCR System (Qiagen) according to the manufacturer’s instruction. RT reactions with miScript II RT Kit (Qiagen) contained 1.0 μg total RNA, 4 μl 5×miScript HiSpec buffer, 2 μl 10×miScript nucleic mix and 2 μl miScript reverse transcriptase mix in each reaction (20 μl). The RT reaction was conducted under the following conditions: 37°C for 60 min and then 95°C for 5 min. After that, the cDNA products from RT reaction were diluted 15 times. PCR was carried out with 1.5 μl of the diluted products in 20 μl PCR reaction containing 10 μl 2×QuantiTect SYBR Green PCR master mix, 2 μl 10×miScript universal primer, 2 μl 10×miScript primer assay. Amplification was performed as follows: 95°C for 15 min, followed by 40 cycles at 94°C for 15 s, 55°C for 30 s and 70°C for 30 s. All reactions were run in triplicate. Relative expression was calculated using the comparative CT method and normalized to the expression of RNU6B.

Results

Sequencing data description

For each sample, we obtained ~14 M clean reads from the raw sequences (Table S1, data available in http://www.ncbi.nlm.nih.gov/Traces/sra/, submission number: SRA060665). The quite equal total number of reads between HepG2 and HepG2/DOX cells will allow a reliable comparison of miRNA distribution and expression profiles in the following steps. To assess the size distribution of small RNAs in each library, we counted the number of clean reads based on the insert length. The most abundant group in both samples was 22 nt in length, as most studies of miRNA size distribution reported in human or animals. Two samples presented different patterns of distribution: tags with 22 nt comprised 64.00% of the total number of small RNAs in HepG2, while only 25.00% in HepG2/DOX small RNA pools (Figure S1). The lower distribution of 22-nt tags in the latter sample might indicate that most miRNAs were down-expressed in HepG2/DOX.

We then summarize the common and specific tags between two samples, including the summary of unique tags and total tags. In
both HepG2 and HepG2/DOX cells, we obtained 932,661 unique tags after removing repeats from the total tags (27,733,155). The two samples shared 6.64% and 89.07% of unique common tags and total common tags. The very few unique common tags indicated that HepG2/DOX presented a distinctive small RNA profile compared to HepG2. HepG2/DOX had more specific small RNAs than HepG2 (unique: 62.40% and 30.96%; total: 8.12% and 2.81% for HepG2/DOX and HepG2, respectively) (Figure S2).

In HepG2 and HepG2/DOX, most 22-nt small RNAs began with the base “U”. The 21-nt small RNAs exhibited a bias to “A” and “U” at first base in HepG2, but only “A” in HepG2/DOX (Figure S3). Both libraries displayed similar compositions of four bases and most sites possessed a major base, which indicated that small RNA sequences from libraries were conserved.

Mapping
With regard to the unique tags, a total of 42.10% (147,647 tags) from HepG2 and 47.79% (307,759 tags) from HepG2/DOX were mapped onto human genomes. Concerning the total tags, about 78.73% (11,033,112 tags) from HepG2 and 73.82% (10,128,686 tags) from HepG2/DOX were mapped onto human genomes. As shown in Figure S4, small RNAs were unevenly distributed across chromosomes between sense and antisense chains. More small RNAs were mapped in the sense chains. For example, there were 25,847 unique tags and 2,332 unique tags in the exon-sense and exon-antisense regions in HepG2, respectively, with ratio of 11:1; while in HepG2/DOX, the ratio was 112:1 (173,619:1,546) (Figure 1A and 1C). As shown in Figure 1B and 1D, the numbers of total tags were 32,526 and 2,985 on the exon-sense and exon-antisense chains in HepG2, while 260,480 and 2,546 in HepG2/DOX.

Categorization and annotation
We categorized the small RNA tags into miRNA, scRNA, tRNA, rRNA, snRNA/snoRNA, repeats, and mRNA fragments. From the annotated small RNAs in Genbank and Rfam (10.1) databases, we obtained 4,056 and 3,190 miRNAs in HepG2 and HepG2/DOX cells, respectively (Figure 1). There were still 55.63% and 42.47% unannotated small RNAs in two samples,

Figure 2. The miRNA expression levels from deep sequencing and validation with qRT-PCR. (A) The scatter plot shows the expression levels of known miRNAs in HepG2 and HepG2/DOX cells. Blue dots: equally expressed miRNAs between HepG2 and HepG2/DOX; Red dots: miRNAs in HepG2/DOX were up-expressed compared to HepG2 (adjusted $P < 0.05$); Green dots: miRNAs in HepG2/DOX were down-expressed compared to HepG2 (adjusted $P < 0.05$). (B,C) The validation of selected up- and down-expressed known miRNAs indicated that the results from deep sequencing were generally agreed well with the qRT-PCR results. (D) The scatter plot shows the expression levels of novel miRNAs in HepG2 and HepG2/DOX cells. (E) The validation of selected novel miRNAs indicated that the results from deep sequencing were generally agreed well with the qRT-PCR results.
doi:10.1371/journal.pone.0054111.g002
which were used for novel miRNA prediction. As for known miRNAs, we referred to the database of miRBase18 and detected 780 mature miRNA (including 270 miRNA-5p and 246 miRNA-3p) and 680 miRNA precursors from HepG2, and 668 mature miRNA (including 231 miRNA-5p and 209 miRNA-3p) and 585 miRNA precursors from HepG2/DOX (Table S2). In total, we got 360 miRNAs shared by both samples, whose expression levels were then normalized and compared.

### Differentially expressed known and novel miRNAs between HepG2 and HepG2/DOX cells

In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted \(P<0.05\)) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1).

To further validate these differentially expressed known miRNAs, 22 individual miRNAs were selected to perform quantitative RT-PCR assay. These 22 selected miRNAs covered both top up-expressed miRNAs (miR-181a-3p, miR-3660, miR-2682-5p, miR-551b-3p, miR-3117-3p, miR-551b-5p, miR-548h-5p, miR-296-3p, miR-4488) and top down-expressed miRNAs (miR-338-3p, miR-486-3p, miR-944, miR-2277-5p, miR-338-5p, miR-139-3p, miR-4427, miR-3186-3p, miR-1269b, miR-3674, miR-3910) in HepG2/DOX cells. As illustrated in Figure 2B and 2C, the Illumina deep sequencing data correlated well with the quantitative RT-PCR results, indicating the reliability of sequencing based expression analysis.

### Table 1. The most significantly differentially expressed miRNAs in HepG2/DOX cells.

| miRNA ID    | log₂(fold change)* | Up/down expression | \(P\) value adjusted | miRNA ID    | log₂(fold change)* | Up/down expression | \(P\) value adjusted |
|-------------|--------------------|--------------------|-----------------------|-------------|--------------------|--------------------|-----------------------|
| hsa-miR-181a-3p | 9.04               | Up                 | 1.56E-23              | hsa-miR-338-3p | –11.63             | Down               | 4.47E-133             |
| hsa-miR-3660   | 7.87               | Up                 | 1.95E-11              | hsa-miR-486-3p | –8.90              | Down               | 2.14E-21              |
| hsa-miR-2682-5p | 7.77               | Up                 | 7.78E-11              | hsa-miR-944   | –8.39              | Down               | 1.61E-15              |
| hsa-miR-551b-3p | 7.39               | Up                 | 9.63E-09              | hsa-miR-2277-5p | –8.01              | Down               | 2.67E-12              |
| hsa-miR-3117-3p | 7.26               | Up                 | 3.73E-08              | hsa-miR-338-5p | –8.01              | Down               | 2.68E-12              |
| hsa-miR-551b-5p | 7.11               | Up                 | 1.49E-07              | hsa-miR-139-3p | –7.96              | Down               | 9.21E-75              |
| hsa-miR-548h-5p | 6.95               | Up                 | 5.93E-07              | hsa-miR-4427  | –7.36              | Down               | 1.58E-08              |
| hsa-miR-296-3p  | 6.60               | Up                 | 8.05E-29              | hsa-miR-3186-3p| –7.01              | Down               | 4.40E-07              |
| hsa-miR-4488   | 5.95               | Up                 | 4.10E-35              | hsa-miR-1269b | –6.74              | Down               | 3.15E-06              |
| hsa-miR-296-5p  | 5.84               | Up                 | 3.88E-78              | hsa-miR-3674  | –6.74              | Down               | 3.16E-06              |
| hsa-miR-4454   | 5.19               | Up                 | 3.07E-85              | hsa-miR-3910  | –6.74              | Down               | 3.17E-06              |
| hsa-miR-4687-3p| 4.37               | Up                 | 8.32E-26              | hsa-miR-642a-3p| –6.74              | Down               | 5.10E-32              |
| hsa-miR-3654   | 3.38               | Up                 | 1.21E-25              | hsa-miR-486-5p| –6.46              | Down               | 2.81E-100             |
| hsa-miR-577    | 2.94               | Up                 | 8.64E-05              | hsa-miR-203   | –6.30              | Down               | 3.19E-89              |
| hsa-miR-4508   | 2.9                | Up                 | 5.94E-06              | hsa-miR-1277-3p| –6.16              | Down               | 3.01E-41              |
| hsa-miR-3687   | 2.49               | Up                 | 2.04E-05              | hsa-miR-1277-5p| –5.90              | Down               | 3.84E-18              |
| hsa-miR-4448   | 2.45               | Up                 | 1.66E-04              | hsa-miR-1250  | –5.71              | Down               | 2.05E-169             |
| hsa-miR-4426   | 2.23               | Up                 | 3.33E-05              | hsa-miR-139-5p| –5.46              | Down               | 3.71E-25              |
| hsa-miR-720    | 2.08               | Up                 | 1.21E-05              | hsa-miR-335-5p| –5.26              | Down               | 2.00E-41              |
| hsa-miR-4485   | 1.71               | Up                 | 6.14E-08              | hsa-miR-362-3p| –5.01              | Down               | 3.36E-10              |
| hsa-miR-877-5p | 1.68               | Up                 | 1.92E-82              | hsa-miR-1255a | –4.92              | Down               | 1.25E-62              |
| hsa-miR-3679-5p| 1.45               | Up                 | 5.33E-04              | hsa-miR-3622a-5p| –4.83             | Down               | 4.30E-09              |
| hsa-miR-21-3p  | 1.40               | Up                 | 7.87E-13              | hsa-miR-1293 | –4.67              | Down               | 2.87E-08              |

Note: *fold change = |HepG2/DOX|/HepG2.

To further validate these differentially expressed known miRNAs, 22 individual miRNAs were selected to perform quantitative RT-PCR assay. These 22 selected miRNAs covered both top up-expressed miRNAs (miR-181a-3p, miR-3660, miR-2682-5p, miR-551b-3p, miR-5117-3p, miR-551b-5p, miR-548h-5p, miR-296-3p, miR-4488, miR-296-5p, miR-4454) and top down-expressed miRNAs (miR-338-3p, miR-486-3p, miR-944, miR-2277-5p, miR-338-5p, miR-139-3p, miR-4427, miR-3186-3p, miR-1269b, miR-3674, miR-3910) in HepG2/DOX cells. As illustrated in Figure 2B and 2C, the Illumina deep sequencing data correlated well with the quantitative RT-PCR results, indicating the reliability of sequencing based expression analysis.

To discover novel candidate miRNAs in HepG2 and HepG2/DOX cells, we predicted the sequences with miRNA stem loop structure and Dicer cleavage sites from unannotated small RNA sequences to be novel miRNAs. A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9
and 13 novel miRNAs were significantly up-expressed and down-expressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05). We selected 6 novel miRNAs for further validation by quantitative RT-PCR assay, including novel-miR-43, novel-miR-65, novel-miR-51, novel-miR-14, novel-miR-35 and novel-miR-27. As a result, the above predicted miRNA candidates could be successfully amplified by quantitative RT-PCR and the level of expression coincided with the sequencing results (Figure 2E). These differentially expressed miRNAs or their combined expression might regulate mRNAs associated with the DOX resistance of HCC cells.

Prediction of miRNA target genes
We predicted the potential target genes of aberrantly expressed miRNAs in HepG2/DOX cells. Based on prediction of Mireap software, these miRNAs were expected to target 31,175 genes in

### Table 2. Significantly differentially expressed novel miRNAs in HepG2/DOX cells.

| miRNA ID             | log2(fold change)* | Up/down expression | P-value | miRNA ID             | log2(fold change)* | Up/down expression | P-value |
|----------------------|--------------------|--------------------|---------|----------------------|--------------------|--------------------|---------|
| hsa-novel-mir-27     | 10.32              | Up                 | 7.84E-55| hsa-novel-miR-43     | -10.14             | Down               | 3.29E-48|
| hsa-novel-mir-35     | 9.95               | Up                 | 5.69E-43| hsa-novel-miR-65     | -9.64              | Down               | 1.24E-34|
| hsa-novel-mir-14     | 9.59               | Up                 | 7.59E-34| hsa-novel-miR-51     | -8.12              | Down               | 3.59E-13|
| hsa-novel-mir-8      | 9.31               | Up                 | 4.43E-28| hsa-novel-miR-41     | -8.08              | Down               | 7.06E-13|
| hsa-novel-mir-12     | 8.84               | Up                 | 8.36E-21| hsa-novel-miR-64     | -7.48              | Down               | 4.18E-09|
| hsa-novel-mir-25     | 7.99               | Up                 | 2.48E-12| hsa-novel-miR-50     | -7.29              | Down               | 3.06E-08|
| hsa-novel-mir-15     | 7.57               | Up                 | 1.23E-09| hsa-novel-miR-72     | -7.29              | Down               | 3.05E-08|
| hsa-novel-mir-17     | 1.39               | Up                 | 1.75E-03| hsa-novel-miR-71     | -7.23              | Down               | 5.87E-08|
| hsa-novel-mir-26     | 1.12               | Up                 | 1.58E-08| hsa-novel-miR-58     | -7.08              | Down               | 2.25E-07|

Note: *fold-change = (HepG2/DOX)/HepG2.
doi:10.1371/journal.pone.0054111.t002

Figure 3. Differentially expressed miRNA-modulated putative targets in the part of MAPK signaling pathway. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was conducted to identify some of the putative targets for the most differentially expressed known and novel miRNAs in the MAPK signaling pathway. Here only part of the pathway was displayed. miRNAs shown in green box are up-regulated while those in blue box were down-regulated.
doi:10.1371/journal.pone.0054111.g003
total. From the results, we observed that a single miRNA could influence thousands of potential targets (e.g. the most up- and down- expressed miRNAs, miRNA-181a-3p and miRNA-338-3p, target 6056 and 11814 genes, respectively) and the same gene could also be targeted by multiple miRNAs (Figure 3).

To explore the biological functions of the most differentially expressed miRNAs (miRNA-181a-3p and miRNA-338-3p), we further checked their potential targets by other three prediction methods: PicTar, miRDB and miRanda. The genes detected by three of four independent tools including Mireap were considered to be the targets of miRNAs. Of the most up-expressed miRNA (miRNA-181a-3p) in HepG2/DOX, one target gene RBM22 supported by three softwares (Mireap, miRDB and PicTar), was expected to be the common targets of seven other significantly differentially expressed miRNAs including miR-21, miR-101, miR-217, miR-590-5p, miR-181b, miR-181c, and miR-181d. Based on GO database, this gene is suggested to participate in cellular response to pressure (GO:0033554), mRNA splicing (GO:0045292, GO:0000398, and GO:0033120), protein translocation and transporting (GO:0090316 and GO:0000060). The target gene of the most down-expressed miRNA (miRNA-338-3p) was UBE2Q1, which was detected by three prediction softwares (Mireap, PicTar and miRanda) and validated by experimental tests as well [38] (http://mirecords.biolead.org). It is also the common candidate target of other ten significantly differentially expressed miRNAs, including miR-21, miR-101, miR-217, miR-590-5p, miR-2682-5p, miR-551b-3p, miR-3117-3p, miR-338-5p, miR-203, miR-195-5p, miR-497-5p, miR-424-5p, miR-16, miR-15b-5p, miR-27a, miR-27b, miR-101 and miR-590-3p. This target gene has ubiquitin-protein ligase activity (GO:0004842) and has been shown to join in the pathways that significantly influence the resistance of chemotherapeutics in HCC therapy [39].

The differentially expressed novel miRNAs were predicted to target 30,240 mRNAs potentially based on Mireap analysis. We further inferred the functions of potential miRNA targets from GO enrichment, including molecular function, cellular component and biological process. Here, we only listed the significant terms belonging to biological process in Table 3 (adjusted P<0.05, Bonferroni Correction). As shown in the table, most of the significant GO terms are related to the metabolic process (e.g. GO:0044238, GO:0060255 and GO:0006139). Other GO categories such as regulation of gene expression (GO:0010468), protein modification process (GO:0006464) and transcription (GO:0006351) are also significantly enriched.

To explore the role that aberrantly expressed miRNAs play in the regulatory networks, we assigned putative targets of novel miRNAs into KEGG pathways. We discovered 6 pathways were enriched, of which the MAPK signaling pathway was the most prominent (adjusted P<0.05, Bonferroni Correction, Table 4). Besides, KEGG analysis offered us further information that MAPK was also one of the important pathways that gathered the putative targets for the top up- and down-expressed known miRNAs, including miR-181a-3p (213 genes), miR-3660 (36 genes), miR-2682-5p (67 genes), miR-551b-3p (19 genes), miR-3117-3p (51 genes) and miR-338-3p (327 genes), miR-486-3p (297 genes), miR-944 (30 genes), miR-2277-5p (159 genes), miR-338-5p (189 genes). Among the analyzed miRNAs, some have common target genes in the MAPK signaling pathway that combined to a systematic network (Figure 3). In HCC, MAPK signaling pathways

| Table 3. The GO term of predicted targets of differentially expressed novel miRNAs. |
|---------------------------------------------|----------------|----------------|----------------|
| GO ID | GO term | Gene count | Percentage (%) | Bonferroni correction |
|----------------|----------------|----------------|----------------|----------------|
| GO:0010468 | regulation of gene expression | 3697 | 16.0% | 0.00064 |
| GO:0060255 | regulation of macromolecule metabolic process | 4098 | 17.8% | 0.00073 |
| GO:0006464 | protein modification process | 3103 | 13.5% | 0.00516 |
| GO:0019222 | regulation of metabolic process | 5101 | 22.1% | 0.00892 |
| GO:0006351 | transcription | 3607 | 15.6% | 0.00902 |
| GO:0043412 | biopolymer modification | 3296 | 14.3% | 0.01392 |
| GO:0044238 | primary metabolic process | 11875 | 51.5% | 0.01610 |
| GO:0006139 | nucleotide,nucleoside, nucleotide and nucleic acid metabolic process | 6208 | 26.9% | 0.02706 |
| GO:0050789 | regulation of biological process | 9522 | 41.3% | 0.03080 |
| GO:0043170 | biopolymer metabolic process | 9444 | 41.0% | 0.03713 |

| Table 4. The KEGG term of predicted targets of differentially expressed novel miRNAs. |
|---------------------------------------------|----------------|----------------|----------------|
| Pathway ID | Pathway | Gene count | Percentage (%) | Bonferroni correction |
|----------------|----------------|----------------|----------------|----------------|
| ko04010 | MAPK signaling pathway | 772 | (3.28%) | 0.00101 |
| ko00230 | Purine metabolism | 1652 | (7.02%) | 0.00515 |
| ko04621 | NOD-like receptor signaling pathway | 236 | (1%) | 0.01924 |
| ko04144 | Endocytosis | 649 | (2.76%) | 0.03904 |
| ko04730 | Long-term receptor signaling pathway | 3 | (0.82%) | 0.03964 |
| ko04971 | Gastric acid secretion | 550 | (2.34%) | 0.04692 |
are up-regulated and generally considered to promote tumor growth [26,40–43]. It has been addressed to participate in the drug-induced tumor cell proliferation and apoptosis in other studies [44–46].

Discussion

miRNAs have recently been shown to play important roles in the development of chemoresistance. Resistance to DOX is a common and representative barrier for successful treatment of cancers. In the present study, we determined the miRNA expression profiles that were differentially expressed between HepG2/DOX and parental HepG2 cells through deep sequencing, which was followed by validation with qRT-PCR. We then carried out function annotation for the predicted target genes of novel miRNAs with GO and KEGG analyses.

The results demonstrated that 23 miRNAs were over-expressed in HepG2/DOX cells, of which miRNA-181a-3p was the most up-regulated. It has been studied in various malignancies showing opposite results. For example, miRNA-181a has been shown to be linked to improved survival in chronic lymphocytic leukemia and acute myelogenous leukemia [47]. It is also indicated that miRNA-181a is an inhibitor of oncogenesis and tumor growth, therefore it can improve prognosis and reduce recurrence risk in gliomas [48]. In hepatocellular cancer cell lines, over-expression of miRNA-181a can diminish adhesion and migration of cancer cells through suppressing glycoprophoprotein OPN expression [49]. In contrast, miRNA-181a expression level has also been reported to be of importance in epithelial cell adhesion molecule/alpha-fetoprotein (EpCAM/αFP) HCC cells quantity, resulting in increased metastasis and poor survival [50]. In our results, miRNA-181a-3p is a specific miRNA in HepG2/DOX cells after normalization. It might come into play through negative regulation of tumor suppressor genes and/or genes that suppress cell differentiation or apoptosis, which contributes to the development of DOX resistance.

Interestingly, most miRNAs were down-regulated in DOX-resistant cells, accounting for about 91.4% of the total miRNAs we presented here. We found miRNA-338-3p was the most down-regulated miRNA in HepG2/DOX cells. It has been reported that miRNA-338 was down-regulated in surgically removed HCC tissues through bead-based microarray [51]. The same group also showed that miRNA-338-3p suppressed HCC cell invasion by targeting smoothed (SMO) and matrix metalloproteinase (MMP)-9 [52]. It is indicated that miRNA-338-3p together with other down-regulated miRNAs might be effective in avoiding resistance or enhancing the effectiveness of HCC to chemotherapy.

Among all the other differentially expressed miRNAs we discovered, quite a lot have been reported by other studies about DOX resistance in HCC. A good example is the down-regulation of miRNA-122 as a liver-specific miRNA in our HepG2/DOX cells [53,54]. It has been shown that over-expression of miRNA-122 can silence its target cyclin G1 and increase DOX sensitivity of HCC cells [23]. MirRNA-122 was also suggested to sensitize HCC cells to chemotherapeutics through modulating expression of MDR. [55]. MiRNA-199a/b-3p is reported to be down-regulated in HCC and it increases sensitivity to DOX-induced apoptosis by targeting mTOR and c-met. We got the same results with lower expression level of miRNA-199a-3p in HepG2/DOX cells [24,56]. Besides, we also found that miRNA-296 have a very high expression level in HepG2/DOX cells. This miRNA can suppress p53 function in cancer cells and might contribute to overcome DOX challenge [57].

Pathway analysis revealed that most significantly regulated miRNAs have putative targets in a common pathway, the MAPK pathway. In line with our predicted targets of known and novel miRNAs, multiple components in this critical mitogenic pathway have been reported to favor the development of drug resistance. For example, an enhanced level of phosphorylated p38 is displayed to be responsible for chemotheraphy resistance in colon and gastric cancer cells [58,59]. The TrkB-BDNF interaction is linked to enhanced survival and resistance to DOX, etoposide, and cisplatin in neuroblastoma [60]. The Ras-RAF-MEK-ERK MAP kinase signaling is also taken as a critical target of anti-drug resistance [61–63]. Therefore, molecular targeting of this critical mitogenic pathway may represent an alternative way for the treatment of HCC.

Since the discovery of miRNAs’ contribution to cancers, several technical platforms have been conducted in elucidating the differential expression of miRNAs, including microarray, qRT-PCR and deep sequencing. Unlike the former approaches focusing on the alteration of individual miRNA, deep sequencing depicts the abundance of each miRNA in the full scale of miRNome. It is one of the most effective and accurate approaches to discriminate the abnormally expressed miRNAs in tumor genomes. To our knowledge, deep sequencing of miRNome related to DOX resistance has never been done in HCC. This direct sequencing offers the possibility to obtain millions of small RNA sequence tags in one shot and detect the length variation of mature miRNA as well as base bias. With benefit of next generation sequencing, we not only displayed the expression differences of modest or even low abundant miRNAs between two samples, but also discovered a number of novel miRNAs.

The contribution of miRNAs in anticancer drug resistance is a very complicated question. The study of linking different miRNAs to various targets and genetic pathways is still in infancy stage. Identification of the differentially expressed miRNAs in human HCC cells related to the resistance of chemotherapy regiments might help to predict the response to chemotherapy. In addition, manipulation of miRNA functions combined with traditional chemotherapy agents might provide a highly promising therapeutic strategy for future treatment of malignant tumors.

Supporting Information

Figure S1 Size distributions of small RNAs in HepG2 and HepG2/DOX cells. 22-nucleotide small RNAs are enriched in both samples, which is in line with the typical size of miRNAs. (TIF)

Figure S2 The proportions of unique common tags and total common tags of small RNAs detected in HepG2 and HepG2/DOX cells. The very few unique common tags indicate that HepG2/DOX cells present distinctive small RNA profiles compared to HepG2 cells. (TIF)

Figure S3 Base compositions of small RNAs in HepG2 and HepG2/DOX cells. Each color represents the small RNA tags whose first base is a certain base. In HepG2 and HepG2/DOX, most 22-nt small RNAs began with the base “U”. (TIF)

Figure S4 Mapping of small RNAs from HepG2 and HepG2/DOX cells onto human chromosomes, respectively. Red lines indicate miRNAs that are located on the antisense chains of genome while the blue ones are on the sense chains. (TIF)
Table S1  Sequencing data of HepG2 and HepG2/DOX cells.

(DOC)

Table S2  Summary of known miRNAs in each sample.

(DOC)

Acknowledgments

We would like to thank Dr. Kay Thurley for critical reading of an earlier version of this manuscript.

References

1. El-Serag HB, Rudolph KL. (2007) Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterol 132:2577–2576.
2. Zheng T, Wang J, Chen X, Liu L. (2010) Role of microRNA in anticancer drug resistance. Int J Cancer 126:2–10.
3. Harrison DJ. (1995) Molecular mechanisms of drug resistance in tumours. J Pathol 175:7–12.
4. Ma J, Dong C, Ji C. (2010) MicroRNA and drug resistance. Cancer Gene Ther 17:523–531.
5. Roberti A, La Sala D, Cinti C. (2006) Multiple genetic and epigenetic interacting mechanisms contribute to clonally selected drug-resistant tumors. Current views and new therapeutic prospective. J Cell Physiol 207:571–581.
6. Allen KE, Weiss GJ. (2010) Resistance may not be futile: MicroRNA biomarkers for chemoresistance and potential therapeutic. Mol Cancer Ther 9:3126–3136.
7. Gottesman MM. (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627.
8. Bartel DP. (2004) Genomics, biogenesis, mechanism, and function. Cell 116:291–297.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435:837–840.
10. Iio A, Nakagawa Y, Hirata I, Naoe T, Akao Y. (2010) Identification of non-coding RNAs: miRNA and CDR1as. Proc Natl Acad Sci U S A 107:18907–18912.
11. Pillai RS. (2005) MicroRNA function: Multiple mechanisms for a tiny RNA? RNA 11:1753–1761.
12. Nishen TW. (2007) Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet 23:243–249.
13. Vasudevan S, Tong Y, Nitz JA. (2007) Switching from repression to activation: MicroRNAs can upregulate translation. Science 318:1931–1934.
14. Negrimi M, Gramaniiteri I, Sabbioni S, Croce CM. (2008) MicroRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 11:500–521.
15. Li W, Xie L, He X, Li J, Tu K, et al. (2008) Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 123:1616–1622.
16. Caldas C, Brenton JD. (2005) Sizing up miRNAs as cancer genes. Nat Med 11:712–714.
17. Zhang H, Huang J, Yang N, Greshock J, Megrave M, et al. (2006) MicroRNA expression profiles in the human cancer cell panel. Mol Cancer Ther 5:1485–1491.
18. Liu H, D’Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, et al. (2010) An integrated database of human miRNA expression and target prediction. Nucleic Acids Res 38:11:1753–1761.
19. Tomokuni A, Eguchi H, Tomimaru Y, Wada H, Kawamoto K, et al. (2011) Mir-199a-21. MicroRNA expression in cytogenetically normal acute myeloid leukemia. Mol Cancer Ther 10:1647–1658.
20. Sterpetti P, Manucci I, Canelarlesi C, Tocci G, Alpini G, et al. (2006) Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by rho gtpase signals. Am J Physiol Gastrointest Liver Physiol 290:G624–632.
21. Yip-Schneider MT, Klein PJ, Wenzi SC, Zani A, Menze A, et al. (2009) Resistance to miR-122-activated protein kinase (mek) inhibitors correlates with up-regulation of the mek/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cell lines. J Pharmacol Exp Ther 329:1063–1070.
22. Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ, et al. (2012) Activation of p53/akt and mapk pathway through a pfdgfbeta-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS One 7:e33379.
23. Bonnas C, Speck E, Schliess FI, Fehrenb H, Dettmann G, et al. (2012) Effects of cold ischemia and inflammatory tumor microenvironment on detection of p53/akt and mapk pathway activation patterns in clinical cancer samples. Int J Cancer 131:1621–1632.
24. Huang H, Nguyen TT, Choow KH, Tan PH, Soo KC, et al. (2003) Over-expression of the miR-122-activated protein kinase (mapk) kinase (mek) gene in hepatocellular carcinoma: Its role in tumor progression and apoptosis. BMC Gastroenterol 3:19.
25. Gedaly R, Angulo P, Hindley J, Daily MF, Chen C, et al. (2011) MicroRNA expression in hepatocellular carcinoma identifies dicer’s role in anticancer drug resistance. J Surg Res 176:342–348.
26. Gedaly R, Angulo P, Hindley J, Daily MF, Chen C, et al. (2011) Pi-103 and forcinib inhibit hepatocellular carcinoma cell proliferation by blocking ras/cap/mipk and pfdgfbeta-dependent pathways synergistically. Anticancer Res 31:495–498.
27. Marcucci G, Radmacher MD, Malawier K, Mrozak K, Ruppert AS, et al. (2008) MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1919–1928.
28. Shi L, Cheng Z, Zhang J, Li R, Zhao P, et al. (2008) Hsa-miR-181a and hsa-miR-181b function as tumor suppressors in human glioma cells. Brain Res 1236:185–193.
29. Bhattacharya SD, Garrison J, Guo H, Mi Z, Markovic J, et al. (2010) MicroRNA-161a regulates osteopontin-dependent metastatic function in hepatocellular carcinoma cell lines. Surgery 148:291–297.
30. Ji J, Yamashita T, Badlhi A, Forges M, Jia HL, et al. (2009) Identification of microRNA-181b by genome-wide screening as a critical player in epcam-positive hepatocarcinoma cells. Hepatology 50:472–480.

Author Contributions

Conceived and designed the experiments: JZ JW WZ. Performed the experiments: YW XL YY JL YY. Analyzed the data: JZ XL YW PZ LZ YL. Wrote the paper: JZ YY.
51. Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, et al. (2009) Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: Mir-338 is downregulated. Hepatol Res 39:786–794.
52. Huang XH, Chen JS, Wang Q, Chen XL, Wen L, et al. (2011) Mir-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol 225:463–472.
53. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, et al. (2008) Liver-specific microRNA mir-122 enhances the replication of hepatitis c virus in nonhepatic cells. J Virol 82:8215–8223.
54. Chang J, Nicolas E, Marks D, Sander C, Lerro A, et al. (2004) Mir-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter cat-1. RNA Biol 1:106–113.
55. Xu Y, Xia F, Ma L, Shan J, Shen J, et al. (2011) MicroRNA-122 sensitizes hcc cancer cells to adriamycin and vincristine through modulating expression of mdr and inducing cell cycle arrest. Cancer Lett 310:160–169.
56. Hou J, Lin L, Zhou W, Wang Z, Ding G, et al. (2011) Identification of mirnomes in human liver and hepatocellular carcinoma reveals mir-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19:232–243.
57. Yoon AR, Gao R, Kaul Z, Choi IK, Ryu J, et al. (2011) MicroRNA-296 is enriched in cancer cells and downregulates p21waf1 mRNA expression via interaction with its 3’ untranslated region. Nucleic Acids Res 39:8078–8091.
58. Paillas S, Boissiere F, Bleau F, Denouel A, Mollevi C, et al. (2010) Targeting the p38 mapk pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res 71:1041–1049.
59. Guo X, Ma N, Wang J, Song J, Bu X, et al. (2008) Increased p38-mapk is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 8:375.
60. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, et al. (2002) Resistance to chemotherapy mediated by trkb in neuroblastomas. Cancer Res 62:6462–6466.
61. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, et al. (2006) Roles of the raf/mek/erk and p38/pten/akt pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249–279.
62. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al. (2007) Roles of the raf/mek/erk pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263–1294.
63. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, et al. (2004) Mechanism of activation of the raf-erk signaling pathway by oncogenic mutations of b-raf. Cell 116:855–867.